The global amniotic products market is projected to reach USD 1.0 billion by 2026 from USD 0.7 billion in 2021, at a CAGR of 8.2% during the forecast period. The growth in this market can be attributed to the growth in the target patient population, rising incidence of burn injuries, awareness programs for wound care treatment and management, rising venture capital investments and government funding, increasing number of traumatic wounds, growing number of amniotic membrane transplantations, and the increasing number of ophthalmology, cosmetic, and orthopedic surgeries. Emerging economies, implementation of 21st-century cures act, and increasing demand for stem cell research and regenerative medicine are expected to offer strong growth opportunities for players in the market. In contrast, the complications and limitation associated with the use of amniotv membrane may challenge market growth to a certain extent. The amniotic products market is segmented based on type, application, end user, and region.
The global amniotic products market is consolidated. The prominent players operating in this market include MiMedx (US), Smith & Nephew (UK), Organogenesis Inc. (US), Integra LifeSciences (US), Stryker (US), Applied Biologics (US), Celularity, Inc. (US), Katena Products, Inc. (US), Lucina BioSciences (US), Next Biosciences (South Africa), Skye Biologics Holdings, LLC (US), Surgenex (US), TissueTech, Inc. (US), Ventris Medical, LLC (US), StimLabs LLC (US), and VIVEX Biologics, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
MiMedx (US) is the leading player in the amniotic products market in 2020. The company has two distribution channels—direct to customers (healthcare professionals and/or facilities) and sales through distributors. The company has a strong presence in the US and is considering business expansion primarily in Europe and the Asia Pacific.
Smith & Nephew (US) accounted for the high share of the amniotic products market in 2020. The company has a wide geographical presence across the US, Europe, Africa, Asia, Australia, and the Middle East, operating in more than 100 countries. In the past three years, the company reported a continuous increase in revenue and R&D expenditure, which has helped it in developing novel products in the market.
Organogenesis Inc. (US) held the third position in the amniotic products market in 2020. Organogenesis is prominently present in the US and generates maximum revenue from the US. The revenue generated outside of the US represents 1% of the company’s total revenue. The company has a robust brand presence, serving more than 4,000 healthcare facilities, inclusive of hospital systems, IDNs, and GPOs. The company has a robust pipeline of products with applications in advanced wound care and surgical & sports medicine market.
Integra LifeSciences (US) held the fourth position in the amniotic products market in 2020. The company’s leading position in this market can be attributed to its strong brand recognition and extensive product portfolio of amniotic products. To maintain its leading position in the market, Integra LifeSciences focuses on product innovation and acquisitions.
Amniotic Products Market by Type (Amniotic Membranes (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Amniotic Suspensions), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospitals, ASCs) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE